ArticleScientific reports2017
Atropine augments cardiac contractility by inhibiting cAMP-specific phosphodiesterase type 4.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Atropine-induced sinus tachycardia protects against exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2020Trial
- A Temporal Reliability and Sustainability Score Framework for Ranking Heart Rate Variability Metrics During Pharmacological Autonomic Blockade in Rats.bioRxiv : the preprint server for biology · 2026Article
- L-Cysteine Ethyl Ester May Overcome Morphine-Induced Respiratory Depression by Activating Muscarinic Receptors.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Pharmacological manipulation of nested oscillations in human iPSC-derived 2D neuronal networks.Neurobiology of disease · 2026Article
- From pharmacophore predictions to pharmaceutical possibilities: an integrated approach to screen MMolecular diversity · 2026Article
- Navigating the Core Challenges of Atropine Therapy in Myopia: A Mechanistic and Clinical Analysis of Dose, Response, and Durability.Journal of ophthalmology · 2026Review
- AAV-microutrophin gene therapy confers durable cardioprotection against pharmacologic and exercise-induced injury in the mdx mouse.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Research progress in myocardial function and diseases related to muscarinic acetylcholine receptor (Review).International journal of molecular medicine · 2025Review
- Severe hypertension after atropine administration a case report.International journal of emergency medicine · 2025Article
- Live Cell Monitoring of Phosphodiesterase Inhibition by Sulfonylurea Drugs.Biomolecules · 2024Article
- Clinical pharmacokinetics of atropine oral gel formulation in healthy volunteers.Clinical and translational science · 2024Article
- Morphological and Physiological Aspects of Mutable Collagenous Tissue at the Autotomy Plane of the StarfishMarine drugs · 2023Review
- Beauty of the beast: anticholinergic tropane alkaloids in therapeutics.Natural products and bioprospecting · 2022Review
- The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy.Scientific reports · 2020Article
- A Bitter Taste in Your Heart.Frontiers in physiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 2 countries.
Funding
Abstract
Atropine is a clinically relevant anticholinergic drug, which blocks inhibitory effects of the parasympathetic neurotransmitter acetylcholine on heart rate leading to tachycardia. However, many cardiac effects of atropine cannot be adequately explained solely by its antagonism at muscarinic receptors. In isolated mouse ventricular cardiomyocytes expressing a Förster resonance energy transfer (FRET)-based cAMP biosensor, we confirmed that atropine inhibited acetylcholine-induced decreases in cAMP. Unexpectedly, even in the absence of acetylcholine, after G-protein inactivation with pertussis toxin or in myocytes from M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.